Quick Take
Pandion Therapeutics (PAND) intends to raise $93.5 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is developing treatments for serious gastrointestinal and liver immune diseases.
PAND is in Phase 1 trials for its lead candidate and still in preclinical stage for its other candidates, so is still at a very early stage.
The IPO may be more suited to institutional investors with a long hold time frame.
Company & Technology
Watertown, Massachusetts-based Pandion was founded to advance a pipeline